Form 8-K · Current Report · Filed 2024-08-01
Alnylam Pharmaceuticals Reports Strong Q2 2024 Financial Results and Key Updates
Alnylam Pharmaceuticals, Inc. reported a 34% year-over-year increase in global net product revenues to $410 million for Q2 2024, driven by robust growth in its TTR business. The company also announced positive topline results from the HELIOS-B Phase 3 study of vutrisiran, showing significant reductions in mortality and recurrent cardiovascular events in patients with ATTR cardiomyopathy. Alnylam updated its 2024 financial guidance, raising combined net product revenue guidance from $1.4-1.5 billion to $1.575-1.650 billion. Key highlights include the modification of the collaboration agreement with Regeneron, which granted Regeneron exclusive rights to cemdisiran as a monotherapy for a $10 million upfront payment. The company also announced a TTR Investor Day on October 9, 2024, and plans to submit a supplemental New Drug Application (sNDA) for vutrisiran to the FDA using a Priority Review Voucher.
- Filer
- Alnylam Pharmaceuticals Inc. ALNY · NASDAQ
- Filed
- Accession
- 0001178670-24-000039
- CIK
- 0001178670
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Financial Statements and Exhibits
Market reaction
Close before filing
$237.46
Next session
+14.6%
Since filing
-13.5%
Latest close
$205.52
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ALNY reporting the same item, with the next session's move:
Exhibits (1)
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Never miss another ALNY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.